CoChat

Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study

Open access
Bramwell, Vivien H.C., Steward, William P., Nooij, Marianne, Whelan, Jeremy, Craft, Alan W., Grimer, Robert J., Taminau, Antonie H.M., Cannon, Steven R., Malcolm, Archie J., Hogendoorn, Pancras C.W., Uscinska, Barbara, Kirkpatrick, Anne L., Machin, David, Van Glabbeke, Martine M. · 1999 · Journal of Clinical Oncology
Cited by 93

The DOI matches its Crossref record.

Abstract

PURPOSE: Studies involving small case series have suggested that malignant fibrous histiocytoma of bone (MFH-B) is a chemosensitive tumor and that chemotherapy may improve survival. In this study, we evaluated clinical and pathologic response rates and survival in a series of patients treated with a consistent chemotherapy regimen of doxorubicin and cisplatin (DOX/DDP). PATIENTS AND METHODS: Study patients were required to have biopsy-proven MFH-B, no previous chemotherapy, and primary or metastatic measurable disease and to be ≤ 65 years of age. Treatment consisted of doxorubicin 25 mg/m 2/d days 1 through 3 and cisplatin 100 mg/m 2 by 4-hour intravenous infusion every 3 weeks for six cycles. In patients with operable primary tumors, chemotherapy was planned to start within 42 days of biopsy, with definitive surgery performed after three cycles. RESULTS: Forty-one patients had operable nonmetastatic limb sarcomas, and 23 (56%) completed six chemotherapy cycles. Limb salvage was possible in 33 patients (80%), and 16 (42%) of 38 assessable specimens showed a good pathologic response (≥ 90% necrosis). Median time to progression was 56 months, and the 5-year progression-free survival rate was 56% (95% confidence interval [CI], 40% to 72%). Median survival time was 63 months, and the 5-year survival rate was 59% (95% CI, 41% to 77%). Patients with a good pathologic response had longer survival times and times to progression than did those with a poor response. Also treated were two patients with locally recurrent and nine with metastatic disease, and these patients had a median survival time of 17.5 months. CONCLUSION: Our study suggests that adjuvant or neoadjuvant chemotherapy with DOX/DDP is beneficial in MFH-B. Good pathologic response rates and survivals are quite comparable with those for osteosarcoma, a related bone tumor for which adjuvant or neoadjuvant chemotherapy is an accepted practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1999.17.10.3260

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 93

Metadata

Authors
Bramwell, V. H. C., Steward, W. P., Nooij, M., Whelan, J., Craft, A. W., Grimer, R. J., Taminau, A. H. M., Cannon, S. R., Malcolm, A. J., Hogendoorn, P. C. W., Uscinska, B., Kirkpatrick, A. L., Machin, D., & Van Glabbeke, M. M.
Venue
Journal of Clinical Oncology
Published
1999-10
Volume
17
Issue
10
Pages
3260-3269
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2106327881
Cited by
93
References
0
FWCI
2.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study. https://app.cochat.ai/papers/10.1200/jco.1999.17.10.3260
The paper
Bramwell, V. H. C., Steward, W. P., Nooij, M., Whelan, J., Craft, A. W., Grimer, R. J., Taminau, A. H. M., Cannon, S. R., Malcolm, A. J., Hogendoorn, P. C. W., Uscinska, B., Kirkpatrick, A. L., Machin, D., & Van Glabbeke, M. M. (1999). Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.10.3260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.